GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BSP:A1ZN34) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (BSP:A1ZN34) Cyclically Adjusted PB Ratio : 9.70 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-05-26), AstraZeneca's current share price is R$67.70. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$6.98. AstraZeneca's Cyclically Adjusted PB Ratio for today is 9.70.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:A1ZN34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.78   Med: 5.6   Max: 10.1
Current: 9.33

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 3.78. And the median was 5.60.

BSP:A1ZN34's Cyclically Adjusted PB Ratio is ranked worse than
93.21% of 692 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs BSP:A1ZN34: 9.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Mar. 2024 was R$20.048. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$6.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 8.95 8.70 8.20 8.11

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=67.70/6.98
=9.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=20.048/131.6000*131.6000
=20.048

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201406 6.500 99.800 8.571
201409 6.308 100.000 8.301
201412 6.842 99.900 9.013
201503 7.015 99.600 9.269
201506 7.502 100.100 9.863
201509 8.929 100.200 11.727
201512 9.461 100.400 12.401
201603 7.182 100.400 9.414
201606 6.103 101.000 7.952
201609 5.603 101.500 7.265
201612 6.563 102.200 8.451
201703 5.348 102.700 6.853
201706 5.924 103.500 7.532
201709 5.660 104.300 7.141
201712 6.488 105.000 8.132
201803 5.572 105.100 6.977
201806 6.274 105.900 7.797
201809 6.452 106.600 7.965
201812 6.369 107.100 7.826
201903 5.116 107.000 6.292
201906 6.637 107.900 8.095
201909 6.366 108.400 7.728
201912 6.844 108.500 8.301
202003 6.689 108.600 8.106
202006 8.064 108.800 9.754
202009 8.364 109.200 10.080
202012 10.204 109.400 12.275
202103 10.324 109.700 12.385
202106 10.008 111.400 11.823
202109 22.573 112.400 26.429
202112 23.886 114.700 27.405
202203 19.452 116.500 21.973
202206 19.509 120.500 21.306
202209 19.816 122.300 21.323
202212 20.892 125.300 21.942
202303 20.046 126.800 20.805
202306 19.517 129.400 19.849
202309 19.754 130.100 19.982
202312 20.621 130.500 20.795
202403 20.048 131.600 20.048

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (BSP:A1ZN34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BSP:A1ZN34) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BSP:A1ZN34) Headlines

No Headlines